Ipilimumab-induced colitis: Experience from a tertiary referral center

Therapeutic Advances in Gastroenterology

Volumn 9, Issue 4, 2016, Pages 457-462

  O'Connor, Anthony ^a   Marples, Maria ^a   Mulatero, Clive ^a   Hamlin, John ^a   Ford, Alexander C ^a,b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

colitis; diarrhoea; infliximab; ipilimumab; melanoma

Indexed keywords

CODEINE; HYDROCORTISONE; INFLIXIMAB; IPILIMUMAB; LOPERAMIDE; PREDNISOLONE;

ADULT; AGED; ARTICLE; COLITIS; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICAL RESEARCH; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; PRESCRIPTION; PRIORITY JOURNAL; TERTIARY CARE CENTER; TREATMENT OUTCOME; VERY ELDERLY;

EID: 84975044041     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X16646709     Document Type: Article

References (17)

1. Andrews S., Holden R., (2012) Characteristics and management of immune related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res 4: 299-307.
2. Beck K., Blansfield J., Tran K., Feldman A., Hughes M., Royal R., et al.(2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T lymphocyte-associated antigen 4. J Clin Oncol 24: 2283-2289.
3. Berman D., Parker S., Siegel J., Chasalow S., Weber J., Galbraith S., et al.(2010) Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 10: 11.
4. Bristol-Myers Squibb Pharmaceutical Limited (2015) Ipilimumab SPC. Available at: http://www.medicines.org.uk/emc/medicine/24779 (. accessed 13 September 2015).
5. Gupta A., De Felice K., Loftus E. Jr., Khanna S., (2015) Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther 42: 406-417.
6. Hodi F., O'Day S., McDermott D., Weber R., Sosman J., Haanen J, et al.(2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723. Erratum in: N Engl J Med 363: 1290.
7. Ibrahim R., Berman D., DePril V., Humphrey W., Chen T., Messina M., et al.(2011) Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol 29: 15.
8. Kwon E., Drake C., Scher H., Fizazi K., Bossi A., van der Eertweghet A., et al.(2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase III trial. Lancet Oncol 15: 700-712.
9. Mowat C., Cole A., Windsor A., Ahmad T., Arnott I., Driscoll R., et al.(2011) Guidelines for the management of inflammatory bowel disease in adults. Gut 60: 571-607.
10. O'Day S., Weber J., Wolchok J., Richards J, Lorigan D, McDermott D., et al.(2011) Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. J Clin Oncol 29: abstract 8554.
11. Reck M., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., et al.(2013) Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II trial. Ann Oncol 24: 75-83.
12. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al.(2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526.
13. Royal R., Levy C., Turner K., Mathur A., Hughes M., Kammula U., et al.(2010) Phase II trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33: 828-833.
14. Slovin S., Higano C., Hamid O., Tejwani S., Harzstark A., Alumkal J., et al.(2013) Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 24: 1813-1821.
15. US National Institutes of Health (2006) Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf (. accessed 4 September 2015).
16. Wolchok J., Neyns B., Linette G., Negrier S., Lutzky J., Thomas L., (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase II, dose-ranging study. Lancet Oncol 11: 155-164.
17. Yang J., Hughes M., Kammula U., Royal R., Sherry R., Topalian S., et al.(2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30: 825-830.